MCL1 and Miyoshi myopathy: This was associated with the induction of BIM expression, and, strikingly, MCL-1 expression was decreased with this treatment combination, which was a significant finding as this is known to play a critical role in driving MM cell survival and has been associated with adverse prognosis in myeloma patients [31, 32].